Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zura BioZURA -0.95%25 Buyback Yield % is -24.93 as of Jul. 26, 2026. GuruFocus rates ZURA with a GF Score™ of 25/100. Among 738 Biotechnology companies, Zura Bio ranks worse than 71% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Zura Bio's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZURA vs KYTX, ARVN, CBIO: Buyback Yield % Comparison
For the Biotechnology subindustry, Zura Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zura Bio Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zura Bio's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Zura Bio's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zura Bio (ZURA) has a Buyback Yield % of -24.93 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zura Bio and its competitors. According to the industry distribution chart, Zura Bio ranks #524 out of 738 companies in the Biotechnology industry, placing it in the top 71%.
Is Zura Bio's Buyback Yield % too high?
Zura Bio's current Buyback Yield % is -24.93. Based on the distribution chart, Zura Bio ranks #524 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Zura Bio has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Zura Bio's Buyback Yield % compare to KYTX and ARVN?
According to the Biotechnology industry distribution chart, Zura Bio ranks #524 out of 738 companies for Buyback Yield %. This places Zura Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Zura Bio and its competitors. Zura Bio's current Buyback Yield % is -24.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zura Bio stock overvalued right now?
Zura Bio (ZURA) has a current Buyback Yield % of -24.93. The current Buyback Yield % is -24.93. Zura Bio's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Zura Bio (ZURA), the current Buyback Yield % is -24.93 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
25GF Score
Get the complete analysis for ZURA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZURA has been successfully added to your 
